Randomized, Controlled, Open Label, Clinical Trial for Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in Hepatocellular Carcinoma Patients With GALNT14-rs9679162-non-TT Genotype
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Adagloxad simolenin (Primary) ; OPT 821 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 02 Dec 2019 Status changed from not yet recruiting to recruiting.
- 30 Jan 2019 Planned initiation date changed from 1 Sep 2018 to 1 Mar 2019.
- 08 Aug 2018 New trial record